Remission From Stage D Heart Failure

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the proportion of subjects who have sufficient improvement in ventricular function after undergoing a standardized Left Ventricular Assist Device (LVAD) plus pharmacologic recovery treatment and testing protocol to allow removal of the LVAD within 18 months.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Louisville
• Collaborator: Thoratec Corporation
• Treatments: Spironolactone

Criteria

Inclusion Criteria:

1. Subject age between 18 - 59 years, inclusive

2. Subject indicated for DT or BTT

3. Subject with severe clinical heart failure resistant to intensive medical therapy and requiring LVAD implantation

4. Subject with LVEF < 25% and cardiomegaly at the time of LVAD implantation as documented by radionuclide or contrast ventriculography or by echocardiography

5. Subject with non-ischemic etiology (confirmed by angiography either within 2 years of implantation or prior to explantation)

6. Subject have undergone HM II implantation within prior 4 weeks or planned for a HM II implant

7. Subject has a history of HF < 5 years.

Exclusion Criteria:

1. Subject has evidence of active acute myocarditis confirmed by histology

2. Subject has a history of previous CVA resulting in significant fixed motor deficit limiting ability to perform exercise testing

3. Subject has been implanted with a mechanical aortic and/or mitral valve(s)

4. Subject had an aortic valve closure

5. Subject diagnosed with a hypertrophic obstructive cardiomyopathy or sarcoidosis

6. Subject with LVEDD below normal confirmed by surface echocardiogram (restrictive cardiomyopathy)

7. Subject has irreversible multi-organ failure

8. Pregnant or lactating women or unwilling to utilize two reliable methods of birth control for women of childbearing age

9. Subject is diagnosed with a psychiatric disease, irreversible cognitive dysfunction or poor psychosocial issues that is likely to impair compliance with the study protocol

10. Subject with any condition, other than heart failure, that could limit survival to less than 2 years

11. Subject has a history of cardiac or other organ transplant

12. Subject is contraindicated to anticoagulation antiplatelet therapy

13. Subject requires acute or chronic renal replacement therapy (e.g. chronic dialysis) within 3 months prior to enrollment

14. Subject participating in any other clinical investigations involving another Mechanical Circulatory Support (MCS) device or heart failure related drug, or investigations which are likely to confound study results or affect study outcome.